BIM
VKTX icon

BlackRock Investment Management’s Viking Therapeutics VKTX Stock Holding History

BlackRock Investment Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-327
Closed – – 4123
2016
Q1 		$0 Hold
327
– – ﹤0.01% 4115
2015
Q4 		$1K Hold
327
– – ﹤0.01% 4065
2015
Q3 		$2K Hold
327
– – ﹤0.01% 4088
2015
Q2 		$2K Buy
+327
New +$2.71K ﹤0.01% 4081

Other funds holding VKTX

SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
AIM
Acrospire Investment Management Chicago, Illinois $33K AUM 23.36% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

BlackRock Investment Management's VKTX Position: Q2 2016 in Review

BlackRock Investment Management sold out of Viking Therapeutics (VKTX) in Q2 2016, closing a stake of 327 shares.

BlackRock Investment Management first reported a position in VKTX in Q2 2015 and held it in 4 quarters. The position peaked at $2K in Q3 2015. 13 funds tracked by Wall St. Rank hold VKTX as of Q2 2016.

  • BlackRock Investment Management reported no remaining Viking Therapeutics position as of Q2 2016 after selling out during the quarter.
  • BlackRock Investment Management sold 327 Viking Therapeutics shares in Q2 2016.
  • BlackRock Investment Management first reported a position in Viking Therapeutics in Q2 2015 and held it in 4 quarters.
  • BlackRock Investment Management's Viking Therapeutics position peaked at $2K in Q3 2015.
  • 13 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2016.

Based on BlackRock Investment Management's 13F filing for Q2 2016, filed 10 Aug 2016.